Tevogen Inc. (TVGN)
TVGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TVGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001860871 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
No annual revenue in SEC XBRL data for this filer.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-14 |
| Cash and burn | $1.1M cash; operating cash flow -$2.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 6,511,540 (2026-08-10); 196,705,067 a year earlier. 1y figure adjusted for split (1-for-50 overall). | Cover page 2026-08-10 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-03-06 | Source 2026-03-06 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-12 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-22 |
| Auditor | KPMG LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $7K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 67,880,267 shares at the 2026-11-13 price; the latest SEC cover count is 6,511,540 as of 2026-08-10. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$5.8M | -$3.0M | $1.1M | $1.7M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$5.4M | -$2.7M | $692K | $1.7M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$4.7M | -$2.2M | $0 | $1.7M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$5.7M | -$3.6M | $1.0M | $1.7M | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$5.5M | -$3.2M | $685K | $1.7M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$10.4M | -$3.3M | $2.0M | $1.7M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$9.4M | -$3.0M | $0 | $1.7M | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$5.9M | -$3.8M | $2.3M | $1.7M | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-06-26 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEF 14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 310 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.3% |
| 1 month | -15.6% |
| 3 months | -8.7% |
| Year to date | -63.7% |
| 1 year | -73.0% |
| From 52-week high | -75.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| TVGNW | Tevogen Inc. Warrant | $0.0256 |
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TECX | Tectonic Therapeutic Inc. | $20.98 | -0.76% | $418.5M |
| IRLA | IRulya Therapeutics Inc. | $37.36 | -6.13% | $405.0M |
| SLBT | SL Science Holding Limited | $0.7195 | -3.42% | $403.5M |
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| ALEC | Alector Inc. | $2.57 | +1.18% | $382.6M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
| CCCC | C4 Therapeutics Inc. | $2.65 | -3.99% | $348.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier